published meta-analysis   sensitivity analysis   studies

janus kinase (JAK) inhibitor in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsMurugesan, 2022 1.00 [0.02; 51.41] 1.00[0.02; 51.41]Murugesan, 202210%100NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 07:32 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 1046,727,818,606,954,964,962,963,1045 - roots T: 290